Logo image of IMVT

IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMVT - US45258J1025 - Common Stock

22.98 USD
-0.19 (-0.82%)
Last: 12/9/2025, 1:21:33 PM
Fundamental Rating

3

Taking everything into account, IMVT scores 3 out of 10 in our fundamental rating. IMVT was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMVT as it has an excellent financial health rating, but there are worries on the profitability. IMVT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMVT had negative earnings in the past year.
IMVT had a negative operating cash flow in the past year.
In the past 5 years IMVT always reported negative net income.
In the past 5 years IMVT always reported negative operating cash flow.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

IMVT's Return On Assets of -79.69% is on the low side compared to the rest of the industry. IMVT is outperformed by 67.98% of its industry peers.
With a Return On Equity value of -89.39%, IMVT perfoms like the industry average, outperforming 49.34% of the companies in the same industry.
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROIC N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

IMVT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMVT has more shares outstanding
There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

IMVT has an Altman-Z score of 33.25. This indicates that IMVT is financially healthy and has little risk of bankruptcy at the moment.
IMVT has a Altman-Z score of 33.25. This is amongst the best in the industry. IMVT outperforms 93.97% of its industry peers.
There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.25
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

IMVT has a Current Ratio of 9.07. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.07, IMVT is doing good in the industry, outperforming 78.72% of the companies in the same industry.
A Quick Ratio of 9.07 indicates that IMVT has no problem at all paying its short term obligations.
The Quick ratio of IMVT (9.07) is better than 78.72% of its industry peers.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 9.07
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

IMVT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.93%.
EPS 1Y (TTM)-27.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.76% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.22%
EPS Next 2Y-4.02%
EPS Next 3Y0.99%
EPS Next 5Y23.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 1B 2B 3B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.02%
EPS Next 3Y0.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOVANT INC

NASDAQ:IMVT (12/9/2025, 1:21:33 PM)

22.98

-0.19 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)02-04 2026-02-04
Inst Owners54.22%
Inst Owner Change-1.36%
Ins Owners1.54%
Ins Owner Change-0.06%
Market Cap4.03B
Revenue(TTM)N/A
Net Income(TTM)-464.56M
Analysts81.74
Price Target38.76 (68.67%)
Short Float %22.17%
Short Ratio9.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.9%
Min EPS beat(2)-7.99%
Max EPS beat(2)0.2%
EPS beat(4)3
Avg EPS beat(4)1.3%
Min EPS beat(4)-7.99%
Max EPS beat(4)12.44%
EPS beat(8)4
Avg EPS beat(8)-3.65%
EPS beat(12)5
Avg EPS beat(12)-6.43%
EPS beat(16)6
Avg EPS beat(16)-5.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.41%
PT rev (3m)-4.2%
EPS NQ rev (1m)0.73%
EPS NQ rev (3m)1.85%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-0.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.75
P/tB 7.75
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0
BVpS2.96
TBVpS2.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 9.07
Altman-Z 33.25
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)154.15%
Cap/Depr(5y)190.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.35%
EPS Next Y-9.22%
EPS Next 2Y-4.02%
EPS Next 3Y0.99%
EPS Next 5Y23.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.74%
EBIT Next 3Y-7.37%
EBIT Next 5YN/A
FCF growth 1Y-105.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.52%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOVANT INC / IMVT FAQ

Can you provide the ChartMill fundamental rating for IMMUNOVANT INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMVT.


What is the valuation status for IMVT stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOVANT INC (IMVT). This can be considered as Overvalued.


What is the profitability of IMVT stock?

IMMUNOVANT INC (IMVT) has a profitability rating of 0 / 10.


Can you provide the financial health for IMVT stock?

The financial health rating of IMMUNOVANT INC (IMVT) is 8 / 10.


What is the expected EPS growth for IMMUNOVANT INC (IMVT) stock?

The Earnings per Share (EPS) of IMMUNOVANT INC (IMVT) is expected to decline by -9.22% in the next year.